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Background: After acquiring a varicella-virus-infection, the virus can reactivate and cause herpes zoster 2 
(HZ), a painful skin rash. A complication of HZ is long-term persistence of pain after rash has resolved (so-3 
called postherpetic neuralgia, PHN). We aimed to describe the epidemiology of HZ/PHN and to estimate 4 
HZ/PHN-related costs in the German statutory-health-insurance (SHI) system (~85% of the total 5 
population). 6 
Methods: Treatment data of one large SHI was utilized, containing data on approximately 240,000 7 
insurant and their utilization of services in 2004-2009. Identification of HZ- and PHN-cases was performed 8 
based on ‘International Statistical Classification of Diseases’ and specific medications using a control-9 
group design. Incidences per 1,000 person-years (PY) and costs-of-illness for one year following HZ-onset 10 
considering the payer and societal perspective were calculated. All amounts were inflated to 2010 Euros. 11 
Population-figures were standardized and extrapolated to the total SHI-population in Germany in 2010.  12 
Results: A mean annual incidence of 5.79 HZ-cases per 1,000 PY was observed, translating into an 13 
estimated 403,625 HZ-cases per year in the total SHI-population. Approximately 5% of HZ-cases 14 
developed PHN. One HZ-case caused on average € 210 and € 376 of costs from the payer and societal 15 
perspective, respectively. The development of PHN generated additional costs of € 1,123 (€ 1,645 societal 16 
perspective). Total annual HZ/PHN-related costs were estimated at € 182 Million (€ 105 Million) to the 17 
society (payer). 18 
Conclusion: HZ and PHN place a considerable burden on the German SHI-system. Since HZ-vaccines will 19 




Before the introduction of routine childhood vaccination against chickenpox (varicella), the 22 
lifetime risk of acquiring a varicella-zoster virus (VZV) infection was almost 100% [1]. After recovery 23 
from varicella, which affects mainly children, the virus remains latent in the dorsal root ganglia of the 24 
infected person [2]. Due to decreasing VZV-specific T-cell-immunity with increasing age, a reactivation 25 
of the virus can occur and manifests as shingles (herpes zoster, HZ) [3,4]. But also other causes (e.g. 26 
HIV or psychological stress) can contribute to the reactivation of the virus [5]. HZ is a self-limiting and 27 
painful rash that usually affects the skin of the trunk or the head for approximately four weeks [6-8]. 28 
About 20 to 30% of individuals develop HZ at least once in their lifetime [9]. The main complication of 29 
HZ is postherpetic neuralgia (PHN), a long-lasting burning and severe pain persisting for months in the 30 
affected skin area after the rash has resolved [10,11]. 31 
In 2006 the European medicine agency (EMA) licensed the first vaccine against HZ and PHN 32 
for people 50 years of age and older [12]. This live-attenuated vaccine demonstrated its efficacy in a 33 
randomized controlled trial including individuals aged ≥60 years, reducing HZ and PHN-incidence by 34 
51% and 67%, respectively [13]. The vaccine’s effectiveness was confirmed in a community setting in 35 
the US among adults aged 60 years or older [14]. A recent clinical trial determined a vaccine efficacy 36 
in preventing HZ in people aged 50-59 years by almost 70% [15]. Another vaccine candidate is 37 
currently tested in a phase III clinical trial for its efficacy in preventing HZ in the elderly [16]. As of 38 
2012, the licensed vaccine was not yet available on the market in most European countries. But it can 39 
be expected, that the vaccine will be available on the German market in the near future. 40 
In order to support the evidence-based decision-making process concerning a potential HZ-41 
vaccination recommendation in Germany, we aimed to describe the epidemiology and to estimate the 42 
cost of HZ and PHN in the German statutory health insurance (SHI) system. 43 
Methods 44 
The data-base 45 
 In Germany, almost 85% of the population (69.6 Million people (February 2012 [17]) is 46 
covered by the statutory health insurance (SHI). As of October 2012, there were in total 144 SHIs in 47 
Germany that offered equal mandatory services to their members. The data-base used in this 48 
retrospective analysis contained a sample of the SHI ’Allgemeine Ortskrankenkasse’ (AOK) Hesse 49 
(which is one of the 16 federal states in Germany) and data from the Regional Association of SHI-50 
Accredited Physicians (KV) of Hesse [18]. Therefore, this data-base combines both, patient-related 51 
billing-data from the SHI and patient-related treatment-documentation from the KV. The combined 52 
data-base covers a population of approximately 240,000 individuals, for which information on age, 53 
sex, and information concerning the insurance status (e.g. employed, retired, etc.) were included. The 54 
following information on services is recorded on a patient-level in the data-base: treatment details in 55 
medical practices (where the outpatient care is organized in Germany), drug prescriptions, diagnoses 56 
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records, and therapeutic appliance, inpatient treatment, sick-pay, co-payment, and sick-leave. Since 57 
the data-base included all institutions of the healthcare system in Germany, hospital admissions, 58 
hospital discharge, and referrals between general practitioners (GPs) and specialists could be tracked 59 
for each individual patient. Therefore, a ‘patient career’ over time and relevant treatment costs could 60 
be identified on an individual basis in a cohort fashion. The general utilization of this data-base was 61 
admitted and approved by the data protection officer of the Ministry of Social Affairs Hesse and the 62 
data protection commissaries of AOK Hesse and KV Hesse. Only anonymous data were used for the 63 
analysis. Furthermore the German guidelines of good practice secondary data analysis were 64 
considered throughout the analyses [19]. 65 
 For the assessment of costs and for the calculation of age-specific incidences, individuals of 66 
all ages with a HZ-diagnosis in 2005 to 2008 were included. To guarantee that only acute cases and 67 
costs for the first year after disease onset are included, we considered for each individual the 68 
observation period of two years (i.e. one HZ-diagnosis-free year before diagnosis, and one year after 69 
HZ-diagnosis). Hence, for cases diagnosed in 2005 we considered the year 2004 to identify and 70 
exclude non-acute cases. On the other hand for cases diagnosed in 2008 we considered 2009 to 71 
identify all relevant costs up to 12 months after the diagnosis. Therefore, the dataset contained patient 72 
data from 2004 to 2009. Costs up to one year after HZ diagnose were considered, because three 73 
month from HZ-onset are already required for the definition of PHN and PHN can persist in average 74 
for 9 month [20,13]. 75 
Identification of Herpes zoster and Postherpetic Neuralgia Cases  76 
Definition of a HZ-case 77 
In the data-base, all individuals with a diagnosis code according to the ‘International Statistical 78 
Classification of Diseases and Related Health Problems’10th Revision (ICD-10) [21] B02.* or G53.0 79 
between 2005 and 2008 were identified. Due to billing guidelines in the outpatient sector, the 80 
physician has to indicate the reliability of the diagnosis, in addition to the ICD-10 code. There are four 81 
types of reliability: 1.) “assured”; 2.) “conjectured”; 3.) “status after disease”; and 4.) “disease 82 
excluded”. To ensure that all potential HZ-cases are considered, we included HZ-cases with 83 
respective ICD-10 codes and “assured” or “conjectured” as diagnosis reliability [22]. Outpatient 84 
diagnoses are documented by the physicians for the SHI (for reimbursement purposes) on a quarterly 85 
basis. However, for the definition of PHN-cases and for the assessment of illness-related costs the 86 
exact calendar date of HZ-diagnosis (with date of onset) was necessary. Therefore, we defined the 87 
calendar date as the date of first HZ-diagnosis based on the earliest date of one of the following 88 
conditions (no hierarchical order): 89 
1) Date of prescription of a HZ-specific drug (e.g. virostatics or specific immunoglobulin) (Table 1); 90 
or 91 
2) Date of prescription of pain-medication or co-analgetics by a physician, who documented the HZ-92 
diagnosis, if there was no prescription of those drugs in the previous quarter less than four weeks 93 
before the initial prescription in the quarter of HZ-onset (Table 1). Date of acute pain medication 94 
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is a sufficient indicator, since reducing pain in the acute HZ-phase is central according to German 95 
guidelines [23]; or  96 
3) Date of hospitalization due to HZ; or 97 
4) Date of start of sick-leave due to HZ; or 98 
5) Date of contact with physician, if there was only one healthcare contact or one diagnosis in the 99 
quarter of diagnosis; or 100 
6) If none of the above-mentioned five conditions was fulfilled, we chose the first contact with the 101 
physician, who first documented the diagnosis, as the exact date of HZ-diagnosis in the quarter of 102 
diagnosis. 103 
Cases documented with ICD10-code G53.0 (PHN) but without the HZ code B02.2 (which is not in 104 
accordance to billing guidelines for physicians) were regarded as HZ-cases. 105 
Definition of a PHN-case 106 
In accordance to previously published studies, we defined PHN as pain persisting at least three 107 
month after HZ-onset [24-28,13,29-31]. A HZ-patient became a PHN-case, if there was a PHN-108 
diagnosis documentation or the initiation of a PHN-related pain therapy. Diagnoses with B02.* or G53 109 
ICD-10 codes [21] causing hospitalization or sick-leave 3 to 6 month after the date of HZ-diagnosis 110 
were considered as a PHN-diagnosis. A PHN-related pain therapy was defined as follows:  111 
1) Absence of a prescription of opioids, antidepressants, or anticonvulsants during the three month 112 
prior to HZ-diagnosis (Table 1), plus 113 
2) At least one prescription of an agent listed in Table 1 within the three month after the HZ-114 
diagnosis, plus  115 
3) A minimum of one prescription of opioids, antidepressants, or anticonvulsants during 90 to 180 116 
days after HZ-diagnosis (Table 1). 117 
Perspectives and cost sectors 118 
Costs were analyzed from the perspective of the SHI (payer perspective) as well as from the 119 
societal perspective (see Table 2). The payer perspective comprised costs for outpatient care, drug 120 
prescription, therapeutic appliance, and hospital stay. Sick-pay as transfer payments was also 121 
included in this perspective. The cost sectors for the societal perspective included all costs of the 122 
payer perspective (except for sick-pay), and in addition costs for sick-leave and patient co-payment. 123 
We accounted the HZ/PHN-related costs up to one year after disease onset. 124 
Data for the following cost sectors were regarded: 125 
Sick-pay (transfer payments): According to the German Social Security Code the SHI covers 126 
70% of the insurant’s gross earning per month after six weeks of work absenteeism (for the first 6 127 
weeks the employer continues to pay the salary).  128 
Outpatient treatment: The claims form, documented by the consulted physician, comprises the 129 
following information: Insurant’s identification number (pseudonymized); quarter and year of diagnosis 130 
(ICD-10 code [21]); physician’s identification number (pseudonymized); service codes with date of 131 
service. During the study period service codes were reimbursed by allowances and point values. 132 
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However, the Euro amount of one point is available after respective quarter. Since the KV of Hesse 133 
provided this data we were able to connect the service codes to the particular Euro amount paid by the 134 
SHI for each time period. Hence, we identified the potential costs for HZ and PHN-treatment in the 135 
outpatient sector. All physician groups (GP and all medical specialist groups, e.g. dermatologists and 136 
ophthalmologists) were considered. How we estimated the effective treatment costs of HZ and PHN 137 
will be described in the ‘Cost-Estimation: Direct diagnosis-linkage and control-group design’ section. 138 
Drug prescription: Each drug on a prescription can be identified by its national unique central 139 
pharmaceutical number (PZN). We linked it to the nationwide uniform pharmacy retail price (PRP) for 140 
2010 or the drug related reference price. Table 1 presents the drugs we considered in accordance to 141 
existing treatment guidelines in Germany as relevant for the treatment of HZ and PHN [23]. 142 
Therapeutic appliance: We considered transcutaneous electrical nerve stimulation (TENS) 143 
devices and low-frequency electrical stimulation devices as relevant for pain treatment in HZ/PHN-144 
management. 145 
Inpatient treatment: From the data-base we used the insurant related information concerning 146 
length of hospital stay and main diagnosis. Since 2004 hospitals receive from SHI an allowance based 147 
on German Diagnosis Related Groups (G-DRG) depending on patient’s age, sex and diagnosis [32]. 148 
Costs due to HZ/PHN-related hospitalization were assessed by linking the main diagnosis (reason for 149 
hospital stay) to the corresponding G-DRG and therefore to the respective Euro amount. 150 
Sick-leave: For cost calculation the human capital approach (HCA) was applied [33]. We 151 
identified HZ/PHN-related sick-leave from ICD-10 codes [21] documented on the available sick-leave 152 
certificates together with information on duration of sick-leave. Since in German claims data more than 153 
one ICD-10 diagnose can be documented per one sick-leave episode, we included only those sick-154 
leave episodes, if they were issued by the GP who documented the HZ/PHN-diagnosis in the quarter 155 
that covers the beginning date of the sick leave episode. Furthermore we identified sick-leave entitled 156 
individuals by their insurance status. Sick-leave entitled individuals were employed, job seeking, 157 
voluntary insured, and in rehabilitation situated individuals. We used the monthly employer’s labor-158 
costs (employee’s monthly gross earnings plus employer’s contribution of social insurance premium 159 
per employee, which is about 28% [34] of the employer’s monthly gross earnings) on age and sex in 160 
Germany broken down on a daily basis [33,35]. These amounts were computed with the number of 161 
sick-leave days per patient. In order to estimate the costs conservatively, we utilized data from the 162 
federal statistic office of Germany, which considered both, full-time and part-time employment mean 163 
gross earnings [36]. 164 
Co-payment: The following co-payments, according to the German Social Security Code for 165 
insurance from the age of 18 were considered in this study: Outpatient contact allowance per quarter 166 
(€ 10), co-payment for certain drugs (Table 1), and therapeutic appliance (10% of price, minimum € 5 167 
and maximum € 10, never more than the price itself). Besides drug co-payment, payers reimburse 168 
certain drugs until the reference price only. The difference between reference price and the PRP has 169 
to be paid by the insured person in addition to co-payments. Furthermore, an allowance per hospital 170 




Cost-Estimation: Direct diagnosis-linkage and control-group design 173 
Inpatient treatment, sick-pay, sick-leave, and certain parts of co-payment were services with a 174 
direct diagnosis-linkage to HZ and PHN-treatment (Table 2). However, not all drug prescriptions (e.g. 175 
pain-medication), outpatient procedures (e.g. general-counseling), therapeutic appliance (e.g. TENS 176 
devices), and co-payments (outpatient contact allowance per quarter) are HZ/PHN-specific, only. In 177 
order to estimate HZ/PHN-costs accurately, we performed a control-group design. Controls were 178 
selected and individually assigned to cases based on the following matching-variables: Age, sex, 179 
treatment costs in the year before the case was diagnosed with HZ, and sick-leave entitlement. We 180 
considered for every case one control for each service sector without direct diagnosis-linkage. The 181 
difference between treatment costs of the case and the control within the year after the HZ-diagnosis 182 
was regarded as the relevant treatment costs due to HZ/PHN. In order to separate PHN-specific costs, 183 
we computed the differences between mean costs of HZ-cases with PHN and mean costs of HZ-cases 184 
without PHN, matched according to age group, sex and sick-leave entitlement. 185 
Statistic and Software 186 
When considering individual cost sectors, we calculated mean costs per user of the specific 187 
service (Table 3). In the section ‘total annual costs’ we computed average HZ- and PHN-costs based 188 
on all HZ/PHN-cases independent from individual utilization (Table 4 and 5). To estimate total annual 189 
costs for HZ- and PHN-treatment in the SHI-population, we computed the number of cases in the SHI-190 
population with the average costs per case and age-group from both perspectives. 191 
Total as well as stratum-specific incidences were estimated along with 95% confidence-192 
intervals (95%-CI). Costs per case were calculated along with bias-corrected and accelerated (BCA) 193 
intervals (95%-CI) using bootstrapping (2000 replicates) [37]. To allow extrapolation of the results from 194 
the regional SHI to the total SHI-population in Germany, all incidence and cost figures were 195 
standardized according to age and sex of the SHI-population in Germany (reference date: 31st of July 196 
2010) [38]. We inflated all monetary amounts on Euros of 2010, by using inflation rates from the 197 
German federal office for statistics [33,39]. 198 
For better comparisons with studies from other countries, we calculated the cost findings from 199 
other countries inflated to 2010 amounts within each study’s country and converted these respective 200 
amounts via the gross domestic product purchasing power parity (GDP PPP) into Euros (Germany as 201 
reference country) according to Welte et al. [40] based on data from the Organization for Economic 202 
Co-operation and Development (OECD) [41]. 203 
Software used was: SQL-Server 2000 Developer Edition 8.00.194 for Windows© 2000 204 
professional (Microsoft, Redmond, WA, USA), SAS® (SAS Institute Inc., Cary, N.C., USA) for 205 





Herpes zoster Incidence 209 
 From 2005 to 2008 we identified in total 6,050 HZ-cases in our data-base, of which 5,384 210 
(87%) had an assured diagnosis reliability. Standardized to the general SHI-population of Germany in 211 
2010, the annual incidence over all age-groups remained stable over these 4 years. The incidence 212 
over the study period was 5.79 (95%-CI: 5.64-5.93) cases per 1,000 PY, which translates into a total 213 
of 403,625 (95%-CI: 393,237-413,013) HZ-cases annually in the total SHI-population in Germany 214 
(Table 4 and 5). With 4,436 HZ-cases, the majority of HZ-cases was 50 years of age and older. In this 215 
age-group (50+ years) the overall incidence was 9.33 (95%-CI: 9.05-9.60) HZ-cases per 1,000 PY 216 
translating into estimated 270,417 (95%-CI: 262,382-278,454) HZ-cases (67% of all HZ-cases) 217 
annually in the total SHI-population aged ≥50 years (Table 4 and 5). Figure 1 presents the incidence 218 
of HZ and the proportion of PHN among HZ-cases by age-group. In 24% of cases the PHN ICD-code 219 
G53.0 was documented without a HZ-code B02.2. 220 
Proportion of HZ-Cases developing PHN 221 
 We identified in our data-base 301 PHN-cases. All PHN-cases were over 30 years of age and 222 
278 of them were at least 50 years old. These figures resulted in a mean proportion of 4.5% (95%-CI: 223 
4.0-5.0) of HZ-cases that developed PHN. Based on the estimated annual number of HZ-cases, 224 
18,160 (95%-CI: 16,144-20,176) PHN-cases were estimated to occur within the total SHI-population in 225 
Germany each year (Table 4 and 5). Similar to the HZ-incidence, the proportion of HZ-cases 226 
developing PHN increased with age (Fig. 1): Among HZ-cases aged ≥50 years 6.0% (95%-CI: 5.3-6.7) 227 
developed PHN, which resulted in the fact that 90% of all PHN-cases can be found in this age-group 228 
(Table 4 and 5). 229 
Costs of Illness 230 
Utilization and costs per user 231 
For all cost sectors, Table 3 provides an overview on the utilization of services and the mean 232 
costs per user for one year following disease onset. The results of the utilization and cost analyses are 233 
presented separately for costs related to HZ (HZ) and PHN-related costs (PHN). As presented in 234 
Table 3, the proportion of users and respective costs varied between the sectors of care and between 235 
HZ and PHN. In brief:  236 
Sick-pay: A low proportion of HZ-cases required sick-pay (Table 3). HZ-cases younger than 30 237 
years did not experience sick-pay. Sick-pay figures became more than 10-fold higher, when 238 
considering PHN.  239 
8 
 
Outpatient: Almost 100% of HZ-cases had at least one outpatient physician contact; among 240 
these about 90% had contact to a GP. All PHN-cases utilized outpatient treatment.  241 
Drug prescription: About 83% of the HZ-cases and 100% of PHN-cases had drug 242 
prescriptions. While 90% of individuals over 50-years of age received drugs, only 45% of the under 243 
twenty-year old HZ-cases did. 244 
Therapeutic appliance: With about 1% among HZ-cases and 3% among PHN-cases, this 245 
treatment option was infrequently applied in HZ/PHN-management. 246 
Inpatient: The proportion of HZ-related hospitalization increased from 0.8% in the youngest 247 
age-group (0-9 years) to about 5% in the oldest individuals (80 years and older). These figures 248 
resulted in hospitalization rates of 2.8% of all HZ-cases and 3.2% of HZ-cases 50 years and older, 249 
respectively. On average an inpatient HZ-case spent 9.4 days in hospital. Mean duration of 250 
hospitalization was associated with age and ranged from 4 days in individuals aged <10 years to 251 
about 12 days in patients 80 years and older (p<0.001). The hospitalization rate among PHN-cases 252 
was about 5-fold higher compared to the rate of HZ-cases. The mean duration of PHN-related 253 
hospitalization in PHN-cases was 14 days (range: 5 days (age-group <60 years) to about 46 days 254 
(age-group 80+). 255 
Sick-leave: About a third of employed or job-seeking HZ-cases (n=1,764, 29.2% of all HZ-256 
cases) in our data experienced sick-leave during their disease. On average a HZ-patient experiencing 257 
sick-leave stayed 12.5 days (range: 8 days (age-group < 20 years) to about 20 days (age-group 60-69 258 
years)) off from work (50+: 15.1 days). Individuals suffering from PHN who experienced sick-leave 259 
stayed about two months off from work (range: Over 20 days (age-group 50-59 years) to near 105 260 
days (age-group 60-69 years)). Hence, PHN-sick-leave costs were five times higher. 261 
Co-payment: Of all HZ-cases, 90% had to afford co-payments. In patient 50 years and older 262 
96% had to co-finance services or treatments out of pocket. However, the average amount was below 263 
€ 13 for HZ-cases and below € 39 for PHN-cases (Table 3). 264 
Total annual Costs 265 
 Total annual HZ-related and PHN-related costs per case and the total costs extrapolated for 266 
the SHI are presented in Table 4 (payer perspective) and Table 5 (societal perspective).  267 
From the payer perspective one HZ-case caused € 210 (95%-CI: 190-230) for HZ-treatment 268 
on average (Table 4). In addition to HZ-specific costs one PHN-case generated PHN-related costs of 269 
€ 1,123 (95%-CI: 831-1,525). Based on these results, we estimated that in 2010 the SHI system in 270 
Germany was faced with a total of € 85 Million for HZ-treatment and additional € 20 Million for PHN-271 
treatment, resulting in a total of € 105 Million (Table 4). Costs per HZ-case increased slightly with age. 272 
As a result and due to the higher number of cases in this age-group, the majority of the total costs 273 
were incurred by persons aged 50 years and older. PHN-related costs per case were higher in middle-274 
aged individuals. Total PHN-related costs did not show a trend by age-group. 275 
From the societal perspective, one HZ-case caused € 376 (95%-CI: 350-403) for HZ-treatment 276 
on average (Table 5). In addition to the HZ-specific costs a PHN-case generated PHN-related costs of 277 
€ 1,645 (95%-CI: 1,213-2,247). When considering the societal perspective (all costs except transfer 278 
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payments) based on SHI-population figures, total costs were € 182 Million (+73%) (Table 5). HZ-279 
related as well as PHN-related costs per case were higher in working-aged individuals than in the 280 
elderly. Despite lower incidence rates, the total costs for HZ and PHN-treatment were highest in 281 
individuals aged between 40 and 59 (€ 74 Million as compared to € 57 Million in the age-group 60-79 282 
or € 26 Million in the age-group 20-39 years), due to costs of sick-leave. 283 
Discussion 284 
 By utilizing a combined dataset, which contained both patient-related billing-data from one 285 
large regional SHI and patient-related treatment-documentation from one regional association of SHI-286 
accredited physicians, we were able to describe the epidemiology of HZ and PHN and to estimate the 287 
costs related to the disease in the SHI system in Germany. With more than 400,000 incident HZ-cases 288 
annually and average costs of € 210 per HZ-case and additional € 1,123 per HZ-case, which 289 
developed PHN, the first treatment year of incident patients poses a considerable clinical and 290 
economic burden to the SHI system in Germany.  291 
In our study population, two third of HZ-cases were 50 years of age and older. The observed 292 
incidence for people aged ≥50 years lies within the range of other studies in Germany that assessed 293 
HZ-incidence in this age-group (3.4 to 9.6 per 1,000 PY) [42,43,22]. The overall incidence of 5.8 HZ-294 
cases per 1,000 PY for the total population is also compatible with the magnitude reported in studies 295 
from other European countries, which ranges between 3.8 and 7.9 cases per 1,000 PY [9,25,44,26,45-296 
47]. For the US and Canada, HZ-incidences were reported in a range between 1.7 to 3.23 HZ-cases 297 
per 1,000 PY [48-51]. 298 
Based on the common PHN-definition (pain persisting at least three month after HZ-rash onset 299 
[24-28,13,29-31]), 4.5% (6.0% in people 50 years and older) of HZ-cases developed PHN in our study 300 
population. Depending on the considered age-groups in other studies, the proportion of HZ-patients 301 
developing PHN ranged between 2.6% and 14.5% in the US [3,52,51], UK [25], Germany [43], France 302 
[26], Spain[46], the Netherlands[28], Australia [53], and Italy[44]. 303 
In our population, 2.6% (3.1% in individuals 50 years and older) of HZ/PHN-patients were in 304 
hospital for an average duration of 10 days. Schiffner-Rohe et al. found a HZ-related hospitalization 305 
rate in Germany of 3.4% for HZ-patients 50 years and over [54]. The proportion of patients with HZ 306 
being hospitalized ranged in countries like France [26], UK [9], USA [51], Australia [53], and Italy [44] 307 
between 1.3% and 3%. The average length of HZ-patients being hospitalized was 7.8 to 14 days in 308 
France [26], Italy [44], and Australia [55,53]. 309 
When comparing our cost estimates to findings from a study applying a similar data-base, that 310 
consisted of data from the SHI and KV in Hesse in 2004 and the target population 50 years and older, 311 
we found lower costs per HZ-case [54]. This is mainly derived due to a lower proportion of HZ-patients 312 
being hospitalized, shorter length of hospital stay, lower costs for sick-leave due to HZ, and due to 313 
methodological differences e.g. range of included pain drugs and differences in cost assessment.  314 
Our costs for an average HZ-cases from the payer perspective are with € 210 in the lower 315 
range of results of other industrialized countries such as the UK (PPP € 190) [56], Spain (PPP € 289) 316 
10 
 
[46], or the US (PPP € 592) [57]. In contrast, when considering costs from the payer perspective for 317 
HZ-cases in elderly, our estimated costs are more than two times higher than the estimates from UK 318 
with PPP € 93 [25]. Also the average costs per PHN-patient is in our study population more than 30% 319 
higher than in Spain (PPP € 767) [46]. By adapting all results to one equal level in terms of reference 320 
year (inflation) and GDP PPP in Euros, the residual differences might be derived, among others, from 321 
different prices, treatment procedures, and study designs. 322 
 The utilization of the AOK Hesse/KV Hesse data-base may, however, have some limitations. 323 
First, our data-base covers one region and one health insurance fund. Patients insured with the AOK 324 
in Hesse may not necessarily be representative of the German SHI-population in general since some 325 
differences between social structure and morbidity among insurances exist [58,59]. Especially findings 326 
concerning the sick-leave data may not necessarily be representative for the total German SHI 327 
population, since insurance population developed historically and there exist differences in the 328 
structure of the employment [60]. Our figures might slightly overestimate the costs of sick-leave 329 
caused by HZ, because general sick-leave statistics from an SHI type like the AOK Hesse are usually 330 
above the average in Germany [61]. And since sick-leave certificates may contain more than one ICD-331 
10 diagnose per sick-leave episode an exact diagnose-linkage with HZ/PHN was sometimes difficulty. 332 
However, since we only included HZ/PHN sick-leave certificates if they were documented by the GP 333 
who diagnosed the HZ or PHN of the respective individual, we were able to minimize inaccuracies in 334 
the estimates of sick-leave. Furthermore, care pathways for HZ/PHN-patients may vary between 335 
regions in Germany. However, since equal services and prices are mandatory for all SHIs in Germany, 336 
since countrywide treatment guidelines for HZ and PHN exist, and since there are no substantial 337 
differences in the disease epidemiology compared to a HZ-incidence study covering almost the whole 338 
SHI in Germany [22], we believe that an extrapolation of our study results to the total SHI-population in 339 
Germany (i.e. 90% of the total population in Germany) seemed justified. 340 
Second, we found a certain miscoding in the data-base: In a significant proportion the PHN 341 
ICD-code was documented without a HZ-code, even though billing guidelines specifically ask for it. 342 
This miscoding might be derived from a lacking uniform definition of PHN. Due to this partially 343 
inaccurate use of ICD-10 code for PHN, we were not able to identify all PHN-cases in the outpatient 344 
sector by diagnosis, but this under detection was corrected via case-identification through treatment 345 
documentation as described in the method section. Since we had to perform both, a control-group 346 
design and a PHN-cost separation step to estimate HZ/PHN-related costs, the estimated costs might 347 
differ slightly from the reality.  348 
Third, a slight overestimation might be derived from prices for drugs, reimbursed by payer 349 
(SHI). As we considered pharmacy retail prices from public registers, we could not consider real prices 350 
paid by a SHI. Since the SHI negotiate prices for (generic) drugs with manufacturers confidentially, the 351 
real prices for drugs considered in this study might be lower. 352 
Fourth, a proposal for health economic evaluations in Germany suggested that for the 353 
estimation of inpatient costs also capital costs per inpatient day (accounting to the societal 354 
perspective) should be considered in addition to G-DRGs [62]. However, since actual data to account 355 
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for these costs are lacking, we decided to neglect this cost factor. This might lead to an 356 
underestimation from a societal perspective.  357 
Fifth, taking sick-pay into account has to be discussed critically. However, we considered 358 
costs for sick-pay as transfer payments, as done by Greiner [63] and by Luce et al. [64] and counted 359 
them to the payer perspective only [33]. Since sick-pay in HZ/PHN in Germany on average seems to 360 
be seldom, these costs only minimally affected costs from the payer perspective.  361 
Finally, we were not able to estimate costs for privately paid therapy (e.g. over-the-counter 362 
drugs, acupuncture, or homeopathic treatments) from our data-base. Because this might be an 363 
important therapy option among HZ/PHN-patients, the costs from societal perspective might be even 364 
higher than estimated from our data-base. Nevertheless, the most relevant medications in HZ/PHN-365 
therapy were considered in our study and therefore the presented results give a valid estimate for the 366 
magnitude of the costs that are related to HZ and PHN in Germany. 367 
 Besides these limitations this study holds several significant benefits. The analysis is based on 368 
a sample of over 240,000 individuals from all ages. Due to the detailed drug prescription information in 369 
the data-base we were able to use in addition to diagnosis-related codes a prescription-approach to 370 
identify potential PHN-cases. Hence, we compensated the partially incorrect PHN-diagnosis coding. 371 
Furthermore, this data-base, with its combination of SHI accounting-data and patient’s treatment 372 
information, allowed very detailed cost estimations by age-groups. Hence, we were able to identify all 373 
HZ/PHN-related cost centers on a patient level. This enabled a comprehensive view on treatment 374 
pathways and cost drivers in HZ/PHN-treatment. Finally, this study is based on a multiple-year-375 
approach. Hence, annual volatility in costs caused by political reform intervention or other causes 376 
could be counteracted. Therefore, these findings provide very detailed input data for upcoming health 377 
economic evaluations of HZ-vaccination, which will inform future decision making processes regarding 378 
a potential HZ-vaccination recommendation in Germany. 379 
Conclusion 380 
 Our findings illustrate the epidemiological and economic impact of Herpes zoster and 381 
postherpetic neuralgia in the German healthcare system, which mainly affects individuals above 50 382 
years of age. Due to an aging population in Germany it can be expected that the annual number of 383 
cases will increase in the future and therefore also the total costs for the healthcare system and the 384 
society. HZ- and PHN-related costs per case and total costs from the payer perspective varied by age-385 
group but without showing a clear trend. From the societal perspective, costs per case and total costs 386 
were highest in the working-age population due to costs for sick-leave. These age-specific differences 387 
in costs need to be taken into account in future analyses when assessing the cost-effectiveness of the 388 
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Range: I = 95% confidence-interval 
Fig. 1 HZ-incidence (Cases per 1,000 person years (PY)) and proportion of HZ-cases developing PHN including 95% confidence intervals.  
Study period: 2005-2008, standardized based on the SHI-population in Germany 
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+
HZ Incidence 1.67 3.18 3.04 3.5 4.13 6.56 9.19 11.24 12.76














































Table 1 HZ/PHN-specific Medication and ATCa Codes considered in the study 
Medication group  Agent  ATC 
Virostatics Aciclovirb J05AB01 
 Famciclovir J05AB09 
 Valaciclovir J05AB11 
 Brivudine J05AB15 
Specific immunoglobulin Idoxuridin (Zostrum) D06BB01 
Topical analgesics  Benzocaine D04AB04/54 
 Capsaicin M02AB52  
  M02AP07/57 
 Lidocaine D04AB01/51 
Non-opioids Metamizole N02BB02 
 Diclofenac M01AB05/55 
 Ibuprofen M01AE01/51 
Opiods Tramadolb N02AX02/52 
 Tilidineb N02AX01/51 
Antidepressants Amitriptyline N06AA09/25 
N06CA01 
 Imipramine N06AA02/03 
 Nortriptyline N06AA10 
N06CA06 
 Desipramine N06AA01 
Anticonvulsants Carbamazepineb N03AF01 
 Gabapentinb  N03AX12 
 Pregabalin N03AX16 
 Phenytoin  N03AB02/52 
aAnatomical Therapeutic Chemical Classification System 
bNo co-payment required 
Medication according to German guidelines [27] 
 
Table I Perspectives and Cost Sectors considered in the Study 













Drug prescription#  No 





Modified and based on illustration in German guidelines[29]; 
#in outpatient treatment; cost of medication in inpatient care is included in inpatient costs 
*in some sectors exists a diagnose linkage in others not; 
 
Table 3 Utilization and Costs of Herpes zoster (HZ) and Postherpetic Neuralgia (PHN) Treatment 
Consumption in 
respective sector 
 Societal Perspective 
Payer Perspective  
Transfer 
payments       
Sick-pay Outpatient Drug prescription 
Therapeutic 
appliance Inpatient Sick-leave Co-payment 
a) Utilization [%] 
HZa 
All ages 0.2# 99.9 83.2 1.0 2.8 32.1# 89.9 
50+ 0.2# 99.9 89.2 1.2 3.2 31.6# 96.0 
PHNb 
All ages 2.7# 100.0 100.0 3.4 15.4 57.3# 93.3 
50+ 2.0# 100.0 100.0 3.2 14.6 45.1# 93.0 
b) Mean annual Cost per User [€] 
HZc 
All ages 380.48 82.13 51.82 58.35 2,984.22 1,367.11 12.12 
50+ 375.84 77.87 55.72 62.74 3,080.85 1,660.24 11.63 
PHNd 
All ages 5,453.67 185.79 210.46 48.36 3,738.21 6,529.99 36.42 
50+ 4,297.04 160.23 219.79 50.96 3,890.62 6,900.65 38.04 
All amounts are in Euro 2010;  
Basic population: aHZ-cases without PHN (total: n=5,749; 50+: 4,158), bPHN-cases (total: n=301; 50+: 278),  
cHZ-related costs; dPHN-related costs; #Basic: Employed or job-seeking cases (total: n=1,724; 50+: 733) 
Table 4 Estimation of total annual costs due to HZ and PHN in the SHI-population in Germany – Payer Perspective  
Age 





















0-9 63  (12-118) 
9,509  
(7,809-11,209) 0.60 n.a. n.a. n.a. 0.60 
10-19 129  (84-184) 
22,540  
(20,172-24,908) 2.90 n.a. n.a. n.a. 2.90 
20-29 185  (119-273) 
25,879  
(22,565-29,194) 4.80 n.a. n.a. n.a. 4.80 






(26-656) 0.43 6.34 






(873-2,267) 3.07 11.62 






(1,382-2,961) 1.89 14.31 






(2,648-4,339) 4.71 20.77 






(5,425-7,731) 7.71 24.72 
























(16,144-20,176) 20.39 105.06 
aAmounts are in Euro 2010; bBased on data found in our study and population figures from 2010 of Statutory Health Insurance  
(90% of Germany’s population); cMean 
Table 5 Estimation of total annual costs due to HZ and PHN in the SHI-population in Germany – Societal Perspective 
Age 





















0-9 63 (12-118) 
9,509 
(7,809-11,209) 0.60 n.a. n.a. n.a. 0.60 
10-19 140 (94-197) 
22,540 
(20,172-24,908) 3.15 n.a. n.a. n.a. 3.15 
20-29 339 (258-442) 
25,879 
(22,565-29,194) 8.77 n.a. n.a. n.a. 8.77 






(26-656) 2.04 17.61 






(873-2,267) 6.74 34.94 






(1,382-2,961) 2.91 39,54 






(2,648-4,339) 7.46 31,50 






(5,425-7,731) 8.01 25,90 
























(16,144-20,176) 29.87 181.74 
aAmounts are in Euro 2010; bBased on data found in our study and population figures from 2010 of Statutory Health Insurance  
(90% of Germany’s population); cMean 
